GeoVax Labs publishes data from Phase 2 trial of next-gen COVID-19 vaccine

GeoVax Labs (GOVX) announced the publication of data from the ongoing Phase 2 trial of its next-generation COVID-19 vaccine in the journal Vaccines. The article, authored by researchers at the City of Hope National Medical Center, can be accessed here: GEO-CM04S1 Publication. The Phase 2 clinical trial is evaluating the safety and immunogenicity of GEO-CM04S1, compared to either the Pfizer (PFE) / BioNTech (BNTX) or Moderna (MRNA) mRNA-based vaccine, in patients who have previously received either an allogeneic hematopoietic cell transplant, an autologous hematopoietic cell transplant or chimeric antigen receptor T cell therapy. These patients have significantly compromised immune system function and generally respond at suboptimal levels after receiving currently available COVID-19 vaccines. The article, titled “Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy”, describes the immune response analyses conducted on the open-label portion of the Phase 2 trial, indicating that GEO-CM04S1 is highly immunogenic in these immunocompromised patients, inducing potent humoral and cellular responses, including neutralizing antibodies against SARS-CoV-2 ancestral virus and variants of concern, including the highly immune-evasive Omicron XBB 1.5 variant.